Prediction of the incidence and persistence of allergic rhinitis in adolescence: A prospective cohort study - 03/02/12
Abstract |
Background |
Predictive models have rarely been used in allergy research and practice. However, they might support physicians in advising patients.
Objective |
The aim of this study was to create predictive models for the incidence and persistence of allergic rhinitis (AR) during adolescence.
Methods |
A prospective population-based cohort study was conducted starting at age 9 to 11 years. Potential risk factors for atopic diseases obtained at baseline in 2810 subjects were used to create predictive logistic regression models for the incidence and persistence of physician-diagnosed AR with current symptoms at age 15 to 18 years.
Results |
Positive skin prick test responses to outdoor allergens at baseline were the most important determinant for both the incidence and persistence of AR until follow-up. For the incidence of AR, positive skin prick test responses to indoor allergens, parental history of asthma, female sex, and not having been breast-fed exclusively for 2 or more months were additional statistically significant independent risk factors. Depending on the number of risk factors present, the probability of the incidence of AR increased from 2% (no risk factors present) to 72% (full model; 95% CI, 58% to 85%). The probability of persistence of AR ranged from 33% (no risk factors present) to 83% (full model; 95% CI, 70% to 97%).
Conclusion |
The course of AR over puberty can be predicted using risk factors that are easy to determine in childhood. Sensitization to outdoor allergens seems to play a much greater role for disease development than sensitization to indoor allergens. This might help pediatricians in advising patients.
Le texte complet de cet article est disponible en PDF.Key words : Allergic rhinitis, disease prediction, adolescence, cohort study
Abbreviations used : AR, AUC, ISAAC, ROC, SOLAR, SPT
Plan
Supported by the Federal Office for Occupational Safety and Occupational Medicine and the Federal Ministry of Labor and Social Affairs (Germany). |
|
Disclosure of potential conflict of interest: E. von Mutius has consulted for Novartis, GlaxoSmithKline, ALK-Abelló, and Protectimmun; has received a speaker’s fee from InfectoPharm; has received research support from Airsonett AB; and is a member of the expert panel for the UK Research Excellence Framework. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 2
P. 397 - février 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?